key: cord-0688399-1bz9eug3 authors: Gatineau, Jérôme; Nidercorne, Charlotte; Dupont, Aurélie; Puiffe, Marie-Line; Cohen, José L; Molinier-Frenkel, Valérie; Niedergang, Florence; Castellano, Flavia title: IL4I1 binds to TMPRSS13 and competes with SARS-Cov2 Spike date: 2021-12-25 journal: bioRxiv DOI: 10.1101/2021.12.23.473686 sha: 407f8bb58c7543dfdeb171ec92d4b6f866a650e3 doc_id: 688399 cord_uid: 1bz9eug3 The secreted enzyme interleukin four-induced gene 1 (IL4I1) is involved in the negative control of the adaptive immune response. IL4I1 expression in human cancer is frequent and correlates with poor survival and resistance to immunotherapy. Nevertheless, its mechanism of action remains partially unknown. Here, we identified transmembrane serine protease 13 (TMPRSS13) as an immune cell-expressed surface protein that binds IL4I1. TMPRSS13 is a paralog of TMPRSS2, whose protease activity participates in the cleavage of SARS-Cov2 Spike protein and facilitates virus induced-membrane fusion. We show that TMPRSS13 is expressed by human lymphocytes, monocytes and monocyte-derived macrophages, can cleave the Spike protein and allow Sars-Cov2 Spike pseudotyped virus entry into cells. We identify regions of homology between IL4I1 and Spike and demonstrate competition between the two proteins for TMPRSS13 binding. These findings may be relevant for both interfering with SARS-Cov2 infection and limiting IL4I1-dependent immunosuppressive activity in cancer. One-Sentence Summary Through binding to its newly identified receptor TMPRSS13, the enzyme IL4I1 interferes with SARS-Cov2 Spike cleavage thereby blocking viral entry into host cells. Negative control of the immune response is achieved through multiple mechanisms, amongst which expression of the enzyme interleukin four-induced gene 1 (IL4I1). IL4I1 is a secreted L-amino acid oxidase that catabolizes the essential amino acid phenylalanine and, to a lesser extent tryptophan and arginine, into the corresponding α -keto acids, H 2 O 2 , and NH 3 (1) . Antigen-presenting cells are the main producers of IL4I1 under physiological conditions (2, 3) . IL4I1 regulates B and T-cell activation and proliferation (3) (4) (5) and facilitates the differentiation of FoxP3 + regulatory T cells from naïve CD4 + T cells (6) . In the context of cancer, IL4I1 is expressed by infiltrating macrophages and occasionally by the tumor cells (7) . In mouse tumor models, IL4I1 facilitates escape from the immune response (8) and in humans, its local expression correlates with decreased survival and a pejorative outcome (9) (10) (11) . The mechanisms of action of IL4I1 are only partially known. The rapid IL4I1-mediated inhibitory effect on TCR signaling, within minutes from T-cell activation, its focal secretion into the synaptic cleft, and its detection on the T-cell membrane (5) , suggest the existence of an IL4I1 receptor. Patients with severe Coronavirus disease 19 , caused by severe acute respiratory syndrome Coronavirus 2 (SARS-Cov2), present profound dysregulation of the immune response, characterized by hyper-inflammation (12) and lymphopenia (13) . Virus entry into cells depends on binding of the spike protein to cellular receptor angiotensin converting enzyme 2 (ACE2) and on its priming by host cell transmembrane serine protease (TMPRSS) 2 (14, 15) . Spike cleavage leads to the liberation of an S1 subunit that contains the receptorbinding domain, while exposing the S2 fragment, which allows fusion of the viral envelop with the cell membrane. The TMPRSS proteins are type II transmembrane serine proteases. Activation of the zymogen requires the cleavage of the C-terminal extracellular part of the protein, which remains attached to the cell surface through intramolecular disulfide bonds (16) . Other proteases of this family have been shown to activate spike-pseudotyped virus (17) . Here, we searched for an IL4I1 receptor at the surface of immune cells and identified We used the ligand receptor capture (LRC)-TriCEPS® technique (18) We thus focused on this protein for subsequent analysis. We cloned the TMPRSS13 cDNA and stably expressed a DYK-tagged protein in HEK cells Thus, IL4I1 and TMPRSS13 directly interact with each other and TMPRSS13 represents an IL4I1-receptor at the surface of T cells. Little information is available concerning physiological TMPRSS13 protein expression, but RT-PCR data indicate that it may be produced by immune cells (20) . Thus, we verified . 5G ). TMPRSS13 belongs to the same family of serine proteases as TMPRSS2, which cleaves SARS-CoV2 spike protein and facilitates envelope fusion with host cell membranes (15) . TMPRSS13 is already known to facilitate the entry of influenza virus and coronavirus into host cells (21) and has been recently shown to cleave SARS-Cov2 spike in cells ectopically expressing TMPRSS13 (17) . We first verified the capacity of TMPRSS13 to cleave the S1/S2 fragment of SARS-CoV viruses using a fluorogenic peptide cleavage assay with the HEK and HEK-T cell lines ( fig. 6A) . Indeed, the expression of TMPRSS13 allowed the cleavage of the SARS-CoV peptide (3.9-fold higher signal than in non-expressing HEK cells) and more efficiently that of the SARS-CoV2 peptide (7-fold increase). Digestion was blocked when the cells were pre-treated with Camostat, a known inhibitor of this family of serine proteases (15) . . 6 B&C) . This corresponded to a more important processing of the spike protein into its fusogenic S2 fragment ( fig. 6D ). Human macrophages, which naturally express TMPRSS13, could be also infected by the spike pseudotyped virus ( fig. 6E ). As both IL4I1 and spike interact with TMPRSS13, we looked for homology between these proteins. The two proteins show a small N-terminal region of homology, corresponding to their signal peptide. We found no homology before the S1/S2 cleavage site of spike. On the contrary, we found the S2 fragment to share moderate homology with IL4I1 ( fig. S4) , which reached 25% identity and 59% similarity in some regions. Most of the similarity resided in the S1/S2 cleavage region, Heptad Region (HR)1, HR2, and fusion domains of spike. Considering this homology, IL4I1 may interfere with the ability of TMPRSS13 to cleave spike. We thus preincubated HEK-T cells with recombinant IL4I1 prior to testing cleavage of the S1/S2 peptide ( fig. 6F) . Indeed, IL4I1 almost completely prevented SARS-Cov2 peptide cleavage. Pre-incubation with recombinant IL4I1 also almost completely abolished the capacity of SARS-CoV2 pseudovirus to infect HEK-T cells ( fig. 6 G&H) . Moreover, the addition of IL4I1 to hMDM before infection with the SARS-CoV2 LVS significantly decreased entry of the virus ( fig. 6I) . Co-IPs of TMPRSS13 and IL4I1 in the presence of the S2 fragment of the spike protein ( fig. 6 J&K) were next performed. When a large excess of IL4I1 (20 µg of S2 per 80 µg of IL4I1) was used, the presence of the S2 fragment decreased IL4I1 binding to TMPRSS13 by approximately 50% (fig. 6J) . When the amount of S2 was equivalent to that of IL4I1, the binding of IL4I1 to HEK-T cells was completely abolished ( fig. 6K) . Thus, IL4I1 can interfere with the interaction between spike and TMPRSS13 and reciprocally, the spike protein interferes with IL4I1 binding to its receptor. This study provides two major findings. First, we show the existence of a new receptor for the immunosuppressive enzyme IL4I1 and identify this protein as the serine protease TMPRSS13. This interaction may be important for IL4I1-mediated immunosuppression. Second, we show that TMPRSS13 facilitates spike cleavage and spike pseudotyped virus can enter immune cells. By interacting with TMPRSS13, IL4I1 and the spike protein can interfere with each other. Although IL4I1 has several effects on the immune system, its mechanism of action remains partially elusive. In particular, the rapid effects on the TCR signaling pathway that have been observed (5) cannot be solely explained by the enzymatic activity of IL4I1, including the recently discovered AHR activation (11) . The secretion of IL4I1 (3), and the observation that it can be found on the surface of T-cells after interaction with the cells that produce it (5), both suggested that IL4I1 can act as a cytokine. Here, using a combination of biochemical and immunological methods, we show that IL4I1 indeed binds to the transmembrane protein TMPRSS13, a serine protease recently shown expressed and important in human cancers and in viral infections (21) (22) (23) . Its enzymatic activity combined with its acting through a receptor make IL4I1 a new "moonlighting" multitasking protein (24) . We show that TMPRSS13 is expressed by various immune cell types, with the percentage of positive cells greatly varying between donors, suggesting that the effect of IL4I1 could vary between individuals. Indeed, previously observed impact of IL4I1 on TCR signaling were donor dependent (5). The expression of TMPRSS13 by T and B lymphocytes may explain, at least partially, the action of IL4I1 on these cells. TMPRSS13 appears to be widely expressed by other circulating populations, suggesting that IL4I1 may have a larger spectrum of action in the immune system than currently known. We observed that the C-terminal cleavage of TMPRSS13 is more prevalent and already present on primary T cells and cell lines where this protease may be already active. Such activation was not visible in primary B cells or in HEK-T cells overexpressing TMPRSS13. Kunitz-type serine protease inhibitors, hepatocyte growth factor activator inhibitor (HAI)-1 or HAI-2 (19) . T lymphocytes do not express these inhibitors and are often negative for other inhibitors, such as serpins (The Human Protein Atlas) (25) . Their absence may explain the pre-activation of TMPRSS13 in T cells. The consequences of such activation are yet to be elucidated. TMPRSS13 belongs to the same family of proteases as TMPRSS2, the protease involved in SARS-Cov2 spike protein cleavage (15) . The role of TMPRSS13 in the processing of envelope proteins was already described for influenza virus and has been recently shown for coronavirus (17) . We confirm that TMPRSS13 can facilitate the entry of SARS-CoV2 into cells that express it. Reciprocally, we have shown that the S2 fragment can block the interaction of IL4I1 with TMPRSS13 as depicted in fig.6 M. Such interference may be exploited to limit the immunosuppressive effect of IL4I1 in situations in which it is detrimental, such as cancer. In conclusion, we have identified TMPRSS13 as the surface receptor for the immunosuppressive enzyme IL4I1 and have shown that IL4I1 and the envelope protein spike Left: IL4I1 binds to TMPRSS13 on the plasma membrane of T lymphocytes and inhibits their activation. Right: The spike S2 fragment binds to TMPRSS13 and prevents IL4I1 from binding to the lymphocyte, possibly blocking its effect. What role for AHR activation in IL4I1-mediated immunosuppression ? Oncoimmunology 10 Dichotomy between factors inducing the immunosuppressive enzyme IL-4-induced gene 1 (IL4I1) in B lymphocytes and mononuclear phagocytes Human IL4I1 is a secreted lphenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation IL-4-Induced Gene 1: A Negative Immune Checkpoint Controlling B Cell Differentiation and Activation IL4-induced gene 1 is secreted at the immune synapse and modulates TCR activation independently of its enzymatic activity The immunosuppressive enzyme IL4I1 promotes FoxP3 + regulatory T lymphocyte differentiation: Immunomodulation The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages IL4I1: an inhibitor of the CD8 + antitumor T-cell response in vivo Emerging Role of IL-4-Induced Gene 1 as a Prognostic Biomarker Affecting the Local T-Cell Response in Human Cutaneous Melanoma Derivation of a fifteen gene prognostic panel for six cancers IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression Clinical features of patients infected with 2019 novel coronavirus in Wuhan Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent Böttcher-Friebertshäuser, TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Progress in Molecular Biology and Translational Science Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity Direct identification of ligand-receptor interactions on living cells and tissues List, Phosphorylation of the type II transmembrane serine protease, TMPRSS13, in hepatocyte growth factor activator inhibitor-1 and -2-mediated cell-surface localization MSPL/TMPRSS13. Front Biosci DESC1 and MSPL Activate Influenza A Viruses and Emerging Coronaviruses for Host Cell Entry TMPRSS13 promotes cell survival, invasion, and resistance to druginduced The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy Moonlighting proteins: An intriguing mode of multitasking Tissue-based map of the human proteome Convergent evolution in the genomics era: new insights and directions Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs Monocytes and Macrophages as Viral Targets and Reservoirs Increased intracellular survival of Salmonella Typhimurium ST313 in HIV 1 infected primary human macrophages is not associated with Salmonella hijacking the HIV compartment Multiple reprobing of Western blots after inactivation of peroxidase activity by its substrate, hydrogen peroxide Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. iScience Jalview Version 2--a multiple sequence alignment editor and analysis workbench We thank the IMRB cytometry and imaging facilities as well the IMAG'IC platform (Institut Cochin) which is a member of the National Infrastructure France BioImaging (ANR-10- Data and materials availability: anti-IL4I1 antibodies are available upon MTA. All data is available in the manuscript or the supplementary data.